Journals / The Anatolian Journal of Cardiology / 2016 / Cilt: 16 - Sayı: 8

mRNA PGC-1α levels in blood samples reliably correlates with its myocardial expression: study in patients undergoing cardiac surgery

Pages
622–629
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Most patients with higher peripheral expression also had increased myocardial expression, so we conclude that the non-invasive estimation of mRNA PGC-1α expression from blood samples provides a good approach of the constitutive status of the mitochondrial protection system regulated by PGC-1α and that this could be used as prognostic indicator in cardiovascular disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a transcriptional coactivator that has been proposed to play a protective role in mouse models of cardiac ischemia and heart failure, suggesting that PGC-1α could be relevant as a prognostic marker.
📊
Key Findings & Data:Our previous studies showed that the estimation of peripheral mRNA PGC-1α expression was feasible and that its induction correlated with the extent of myocardial necrosis and left ventricular remodeling in patients with myocardial infarction.
💡
Conclusion & Impact:Conclusions: Most patients with higher peripheral expression also had increased myocardial expression, so we conclude that the non-invasive estimation of mRNA PGC-1α expression from blood samples provides a good approach of the constitutive status of the mitochondrial protection system regulated by PGC-1α and that this could be used as prognostic indicator in cardiovascular disease.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Peroxisome proliferator-activated receptor-&#947; coactivator-1&#945; (PGC-1&#945;) is a transcriptional coactivator that has been proposed to play a protective role in mouse models of cardiac ischemia and heart failure, suggesting that PGC-1&#945; could be relevant as a prognostic marker. Our previous studies showed that the estimation of peripheral mRNA PGC-1&#945; expression was feasible and that its induction correlated with the extent of myocardial necrosis and left ventricular remodeling in patients with myocardial infarction. In this study, we sought to determine if the myocardial and peripheral expressions of PGC-1&#945; are well correlated and to analyze the variability of PGC-1&#945; expression depending on the prevalence of some metabolic disorders.Methods: This was a cohort of 35 consecutive stable heart failure patients with severe aortic stenosis who underwent an elective aortic valve replacement surgery. mRNA PGC-1&#945; expression was simultaneously determined from myocardial biopsy specimens and blood samples ob-tained during surgery by quantitative PCR, and a correlation between samples was made using the Kappa index. Patients were divided into two groups according to the detection of baseline expression levels of PGC-1&#945; in blood samples, and comparisons between both groups were made by chi-square test or unpaired Student s t-test as appropriate.Results: Based on myocardial biopsies, we found that mRNA PGC-1&#945; expression in blood samples showed a statistically significant correlation with myocardial expression (Kappa index 0.66, p<0.001). The presence of higher systemic PGC-1&#945; expression was associated with a greater expression of some target genes such as silent information regulator 2 homolog-1 (x-fold expression in blood samples: 4.43±5.22 vs. 1.09±0.14, p=0.044) and better antioxidant status in these patients (concentration of Trolox: 0.40±0.05 vs. 0.34±0.65, p=0.006). Conclusions: Most patients with higher peripheral expression also had increased myocardial expression, so we conclude that the non-invasive estimation of mRNA PGC-1&#945; expression from blood samples provides a good approach of the constitutive status of the mitochondrial protection system regulated by PGC-1&#945; and that this could be used as prognostic indicator in cardiovascular disease.

🔖

Cite This Article

ANDRES, O. F., PAREDES, F. A., MONSALVE, M., MILARA, J., SORIANO, F. R., HERVAS, S. G., MENA, A., FACILA, L., HORNERO, F., MORELL, S., LEON, J. M., CORTIJO, J. (2016). mRNA PGC-1α levels in blood samples reliably correlates with its myocardial expression: study in patients undergoing cardiac surgery. The Anatolian Journal of Cardiology, Cilt: 16 - Sayı: 8, 622–629. https://ajindex.com/articles/366842

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardio-vasc Res 2008; 79: 208-17
  2. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res 2005; 66: 562-73
  3. Ding L, Liang X, Zhu D, Lou Y. Peroxisome proliferator-activated re-ceptor alpha is involved in cardiomyocyte differentiation of murine embryonic stem cells in vitro. Cell Biol Int 2007; 31: 1002-9
  4. Duncan JG, Finck BN. The PPARα- PGC-1α axis controls cardiac energy metabolism in healthy and diseased myocardium. PPAR Res 2008; 2008: 253817
  5. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabe-tes. Nat Genet 2003; 34: 267-73
  6. Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 2010; 17: 446-52
  7. Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, et al. Ex-cessive cardiac insulin signaling exacerbates systolic dysfunction in-duced by pressure overload in rodents. J Clin Invest 2010; 120: 1506-14
  8. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci USA 2006; 103: 10086-91
  9. Sun CK, Chang LT, Sheu JJ, Wang CY, Youssef AA, Wu CJ, et al. Losartan preserves integrity of cardiac gap junctions and PGC-1 alpha gene expression and prevents cellular apoptosis in remote area of left ventricular myocardium following acute myocardial in-farction. Int Heart J 2007; 48: 533-46
  10. Fabregat-Andres O, Tierrez A, Mata M, Estornell-Erill J, Ridocci-Soriano F, Monsalve M. Induction of PGC-1alpha expression can be detected in blood samples of patients with ST-segment eleva-tion acute myocardial infarction. PLoS One 2011: 6: e26913
  11. Fabregat-Andrés O, Ridocci-Soriano F, Estornell-Erill J, Corbi-Pas-cual M, Valle-Muñoz A, Berenguer-Jofresa A, et al. Blood PGC-1αconcentration predicts myocardial salvage and ventricular remod-eling after ST-segment elevation acute myocardial infarction. Rev Esp Cardiol 2015; 68: 408-16
  12. Uguccioni G, D’souza D, Hood DA. Regulation of PPARγ coactivator-1α function and expression in muscle: effect of exercise. PPAR Res 2010 Aug 19. Epub ahead of print.